Загрузка...
Dupilumab and COVID‐19: What should we expect?
Coronavirus disease 2019 (COVID‐19) is a pandemic disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) with high morbidity and mortality. There are very limited data on the interference of immunomodulating drugs on the risk of infection and on the course of the disease. In...
Сохранить в:
| Опубликовано в: : | Dermatol Ther |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley & Sons, Inc.
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7267436/ https://ncbi.nlm.nih.gov/pubmed/32362061 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dth.13502 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|